Patents by Inventor Samuel Kayman

Samuel Kayman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion glycoproteins
    Patent number: 5952474
    Abstract: Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: September 14, 1999
    Assignee: The Public Health Research Institute of the City of New York, Inc.
    Inventors: Samuel Kayman, Abraham Pinter
  • Fusion glycoproteins
    Patent number: 5643756
    Abstract: Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: July 1, 1997
    Assignee: The Public Health Research Institute of the City of New York, Inc.
    Inventors: Samuel Kayman, Abraham Pinter